Fexofenadine Hcl Tablet
NDC Package 73581-009-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Fexofenadine Hcl tablets is fexofenadine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. This formulation utilizes a tablet delivery system. Marketed by Yyba Corp, this product is identified by NDC 73581-009 and is authorized under FDA application ANDA204097.

Identification & Billing

NDC Package Code
73581-009-01
Package Description
10 TABLET in 1 BOTTLE
Product Code
73581-009
11-Digit Billing Format
73581000901
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fexofenadine Hcl
Non-Proprietary Name
Fexofenadine Hcl
Substance Name
Fexofenadine Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
FEXOFENADINE HYDROCHLORIDE 180 mg/1
Pharmacologic Class
Usage Information
Fexofenadine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.

Regulatory & Marketing

Labeler Name
Yyba Corp
Product Type
Human Otc Drug
FDA Application #
ANDA204097
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-19-2016
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73581-009). Click a package code to view its specific billing and regulatory data.

73581-009-04
40 TABLET in 1 BOTTLE
73581-009-10
100 TABLET in 1 BOTTLE
73581-009-20
200 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73581-009-01 identifies a specific commercial package of 10 tablet in 1 bottle of Fexofenadine Hcl, a human over the counter drug labeled by Yyba Corp. This tablet is formulated for oral use and contains fexofenadine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Yyba Corp on August 19, 2016. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Fexofenadine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.

How is this Yyba Corp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73581000901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73581-009-01
11-Digit CMS (5-4-2)
73581-0009-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.